Trial0
Sign inMap the options

Expanded-access program · NCT05356312 · AVAILABLE

Glioblastoma and Individualized Therapies

Sponsor: Zentrum fur Humangenetik Tuebingen

Request access helpRegistry record ↗

Summary

The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.

Interventions

  • Vaccination · BIOLOGICAL

    Personalized neoantigen vaccination

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* malignant glioma, IDH WT

Exclusion Criteria:

* na

Sites (1)

  • Zentrum für Humangenetik Tübingen, Tübingen, Germany · AVAILABLE

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2024-03-01.